Summary
Like proteomics more generally, neuroproteomics has recently been linked to the discovery of biochemical markers of central nervous system (CNS) injury and disease. Although neuroproteomics has enjoyed considerable success in discovery of candidate biomarkers, there are a number of challenges facing investigators interested in developing clinically useful platforms to assess biomarkers for damage to the CNS. These challenges include intrinsic physiological complications such as the blood–brain barrier. Effective translation of biomarkers to clinical practice also requires development of entirely novel pathways and product development strategies. Drawing from lessons learned from applications of biomarkers to traumatic brain injury, this study outlines major elements of such a pathway. As with other indications, biomarkers can have three major areas of application: (1) drug development; (2) diagnosis and prognosis; (3) patient management. Translation of CNS biomarkers to practical clinical platforms raises a number of integrated elements. Biomarker discovery and initial selection needs to be integrated at the earliest stages with components that will allow systematic prioritization and triage of biomarker candidates. A number of important criteria need to be considered in selecting clinical biomarker candidates. Development of proof of concept assays and their optimization and validation represent an often overlooked feature of biomarker translational research. Initial assay optimization should confirm that assays can detect biomarkers in relevant clinical samples. Since access to human clinical samples is critical to identification of biomarkers relevant to injury and disease as well as for assay development, design of human clinical validation studies is an important component of translational biomarker research platforms. Although these clinical studies share much in common with clinical trials for assessment of drug therapeutic efficacy, there are a number of considerations unique to these efforts. Finally, platform selection and potential assay commercialization need to be considered. Decisions regarding whether or not to seek FDA approval also significantly influence translational research structures.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Haskins, W.E., Kobeissy, F.H., Wolper, R. A., Ottens, A.K., Kitlen, J. W., McClung, S. H., O’Steen, B.E., Chow, M.M., Pineda, J.A., Denslow, N.D., Hayes, R.L., and Wang, K.K. W. (2005) Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry. J. Neurotrauma 22, 629–644.
Ottens, A.K., Kobeissy, F.H., Wolper, R.A., Haskins, W.E., Hayes, R.L., Denslow, N.D., and Wang, K.K. W. (2005) A multidimensional differential proteomic platform using dual phase ion exchange chromatography polyacrylamide gel electrophoresis/reversed phase liquid chromatography tandem mass spectrometry (CAX-PAGE). Anal. Chem. 77, 4836–4845.
Wang, K.K.W., Ottens, A.K., Liu, M.C., Lewis, S.B., Meegan, C., Oli, M. W., Tortella, F.C., and Hayes, R.L. (2005) Proteomic identification of biomarkers of traumatic brain injury. Exp. Rev. Proteomics. 2, 603–614.
Ottens, A.K., Kobeissy, F.H., Haskins, W.E., Golden, E.C., Zhang, Z., Chen, S.S., Hayes, R.L., Wang, K.K.W., and Denslow, N.D. (2006) Neuroproteomics in Neurotrauma. Mass Spectrom. Rev. 25, 380–408.
Kobeissy, F.H., Ottens, A.K., Zhang, Z., Liu, M.C., Denslow, N.D., Dave, J. R., Tortella, F. C., Hayes, R.L., and Wang, K.K.W. (2006) Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol. Cell. Proteomics 5, 1887–1898.
Ottens, A.K., Golden, E.C., Bustamante, L., Hayes, R.L., Denslow, N.D., and Wang, K.K.W. (2008) Proteolysis of multiple myelin basic protein isoforms after Neurotrauma: Characterization by mass spectrometry. J. Neurochem. 104, 1404–1414.
Ottens, A.K., Kobeissy, F.H., Fuller, B.F., Liu, M.C., Oli, M.W., Hayes, R.L., and Wang, K. K. (2007) Novel neuroproteomic approaches to studying traumatic brain injury. Prog. Brain Res. 161, 401–418.
Papa, L., Robinson, G., Oli, M., Pineda, J., Demery, J., Brophy, G., Robicsek, S.A., Gabrielli, A., Robertson, C.S., Wang, K.K., and Hayes, R.L. Use of biomarkers for diagnosis and management of traumatic brain injury patients. Exp. Opin. Med. Diag. 2, 937–945.
Kobeissy, F.H., Sadasivan, S., Oli, M., Robinson, G., Larner, S., Zhang, Z., Hayes, R., and Wang, K.K. (2008)Neuroproteomics and systems biology-based discovery of protein biomarkers for TBI and clinical validation. Clin. App. 2, (10–11) 1467–1483.
Schonberger, S.J., Edgar, P.F., Kydd, R., Faull, R.L., and Cooper, G.J. (2001) Proteomic analysis of the brain in Alzheimer’s disease: Molecular phenotype of a complex disease process. Proteomics 1, 1519–1528.
Yealy, D.M., and Hogan, D.E. (1991) Imaging after head trauma. Who needs what? Emerg. Med. Clin. N. Am. 9, 707–717.
Vollmer, D.G., and Dacey, R.G., Jr. (1991) The management of mild and moderate head injuries. Neurosurg. Clin. N. Am. 2, 437–455.
Saatman, K.E., Duhaime, A.C., Bullock, R., Maas, A.I., Valadka, A., Manley, G.T., and Workshop Scientific Team and Advisory Panel Members. (2008) Classification of traumatic brain injury for targeted therapies. J. Neurotrauma 25, 719–738.
Pineda, J.A., Lewis, S.B., Valadka, S.B., Papa, L., Hannay, H. J., Heaton, S., Demery, J. A., Liu, M.C., Aikman, J.M., Akle, V., Brophy, G.M., Tepas, J.J., III, Wang, K.K.W., Robertson, C.S., and Hayes, R.L. (2007) Clinical significance of αII-spectrin breakdown products in CSF after severe TBI. J. Neurotrauma 24, 354–366.
Murray, G.D., Barer, D., Choi, S., Fernandex, H., Gregson, B., Lees, K.R., Maas, A.I., Marmarou, A., Mendelow, A.D., Steyerberg, E., Taylor, G.S., Teasdale, G.M., and Weir, C. J. (2005) Design and analysis of Phase III trials with ordered outcome scales: The concept of the sliding dichotomy. J. Neurotrauma 22, 511–517.
Pike, B.R., Flint, J., Dutta, S., Johnson, E., Wang K.K.W., and Hayes, R.L. (2001) Accumulation of non-erythroid αII-spectrin and calpain-cleaved αII-spectrin breakdown products in cerebrospinal fluid after TBI in rats. J. Neurochem. 78, 1297–1306.
Pike, B.R., Flint, J., Dave, J.R., Lu, X.C., Wang, K.K., Tortella, F.C., and Hayes R.L. (2003) Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived αIIspectrin in CSF after middle cerebral artery occlusion in rats. J. Cereb. Blood Flow Metab. 24, 98–106.
Ringger, N.C., O’Steen, B.E., Brabham, J. G., Siler, X., Pineda, J., Wang, K.K.W., and Hayes, R.L. (2004) A novel marker for traumatic brain injury: CSF αII-spectrin breakdown product levels. J. Neurotrauma, 21, 1443–1456.
Warren, M.W., Kobeissy, F.H., Liu, M.C., Hayes, R.L., Gold, M.S., and Wang, K.K. W. (2005) Concurrent calpain and caspase-3 mediated proteolysis of αII-spectrin and tau in rat brain after methamphetamine exposure: A similar profile to TBI. Life Sci. 78, 301–309.
Liu, M.C., Akle, V., Zheng, W., Kitlen, J., O’Steen, B., Larner, S.F., Dave, J.R., Tortella, F.C., Hayes, R.L., and Wang, K.K.W. (2006) Extensive degradation of myelin basic protein isoforms by calpain following TBI. J. Neurochem. 98, 700–712.
Warren, M.W., Kobeissy, F.H., Liu, M.C., Hayes, R.L., Gold, M.S., and Wang, K.K. W. (2006) Ecstasy toxicity: A comparison to methamphetamine and TBI. J. Addict. Dis. 25, 115–123.
Warren, M.W., Zheng, W., Kobeissy, F.H., Liu, M.C., Hayes, R.L., Gold, M.S., Larner, S.F., and Wang K.K.W. (2006) Calpain and caspase mediated αII-spectrin and tau proteolysis in rat cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure. Int. J. Neuropsychopharm. 10, 479–489.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Hayes, R.L., Robinson, G., Muller, U., Wang, K.K.W. (2009). Translation of Neurological Biomarkers to Clinically Relevant Platforms. In: Ottens, A., Wang, K. (eds) Neuroproteomics. Methods in Molecular Biology, vol 566. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59745-562-6_20
Download citation
DOI: https://doi.org/10.1007/978-1-59745-562-6_20
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-934115-84-8
Online ISBN: 978-1-59745-562-6
eBook Packages: Springer Protocols